Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) — Agile Therapeutics, Inc. (Nasdaq:AGRX) (“Agile Therapeutics” or the “Company”), a women’s healthcare company, today announced the pricing of its public offering of an aggregate of 1,896,286 shares of its common stock (or pre-funded warrants in lieu thereof), together with accompanying common stock warrants, at a public offering price of $3.9551 per share (or pre-funded warrant) and accompanying warrants. Each share of common stock (or pre-funded warrant) was sold in the offering together with a Series C-1 warrant to purchase one share of common stock at an exercise price of $3.69 per share and a Series C-2 warrant to purchase one share of common stock at an exercise price of $3.69 per share. The Series C-1 warrants are exercisable immediately and will expire five years from the date of issuance, and the Series C-2 warrants are exercisable immediately and will expire eighteen months from the date of issuance. Total gross proceeds from the offering, before deducting the placement agent’s fees and other offering expenses, are expected to be approximately $7.5 million.
Related news for (AGRX)
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, DM, AGRX on Behalf of Shareholders
- SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AAN, TBNK, AGRX, UMBF on Behalf of Shareholders
- AGRX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Agile Therapeutics, Inc. Is Fair to Shareholders
- Agile Therapeutics Announces Delisting from Nasdaq
- Correction – Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024